Home › Rheumatoid Arthritis › Missouri › St. Louis
Rheumatoid Arthritis clinical trials in St. Louis, MO
4 studies for Rheumatoid Arthritis are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- and 1 more
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RecruitingPhase 1
- Research Site, St Louis
A Study of AZD0120 in Autoimmune Diseases
RecruitingPhase 1
- Research Site, St Louis
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RecruitingPhase 2
- Research Site, St Louis
About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, and stiffness in your joints. Your risk increases as you become an older adult.
More about Rheumatoid Arthritis on MedlinePlus
Rheumatoid Arthritis trials in other cities
- Houston, TX11 studies
- New York City, NY10 studies
- Durham, NC8 studies
- Dallas, TX7 studies
- Aurora, CO7 studies
- Altoona, PA7 studies
- Boston, MA7 studies
- Plantation, FL6 studies
- San Diego, CA6 studies
- Chicago, IL6 studies
- West Palm Beach, FL5 studies
- Miami, FL5 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Cancer (all types)46 studies
- Prostate Cancer46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.